BRISTOL MYERS SQUIBB CO
BMYNYSE · SIC 2834
$60.74
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↑ +34.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$124.3B
Enterprise Value
$158.0B
P/E
17.0
P/S
2.6
P/B
6.2
EV/EBITDA
—
PEG
3.1
FCF Yield
9.6%
Dividend Yield
4.1%
Revenue (TTM)
$48.5B
Net Income (TTM)
$7.3B
Free Cash Flow (TTM)
$11.9B
Gross Margin
—
Operating Margin
—
Net Margin
15.0%
ROE
36.3%
ROIC
—
Debt / Equity
2.2
Net Cash
-$33.7B
Return 1Y
+32.5%
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
- CEO
- Giovanni Caforio
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 34,300
- Headquarters
- New Jersey
- Website
- bms.com
Management & directors
- Short Bartie WendyEVP, Corporate Affairs
- Lenkowsky AdamEVP, Chief Commercial Officer
- Elkins David VEVP, Chief Financial Officer
- Shanahan KarinEVP, Chief Supply Chain & Ops
- Boerner Christopher S.Chief Executive Officer
- Gallman CariEVP, General Counsel
- Hoch LynellePresident, Cell Therapy Org.
- Holzer Phil MSVP and Controller
- Meyers Gregory ScottEVP, Chief Digital & Tech Off.
- Plenge Robert MEVP, Chief Research Officer
- Poole Ahn AmandaEVP, Chief People Officer
- Hickey BenjaminPresident, RayzeBio Org.
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
BMY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$11.5B↑ +2.6%
Diluted EPS$1.31↑ +9.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Gross profit | $30.7B | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | -$9.0B | $7.0B | $6.3B | $8.0B | -$8.9B | $7.1B |
| Diluted EPS | -$3.99 | $3.12 | $2.95 | $3.86 | -$4.41 | $3.46 |
| Operating cash flow | $14.1B | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B |
| Free cash flow | $13.3B | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| Gross margin | 72.3% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.2B | $11.9B | $12.3B | $11.2B | $12.3B | $12.2B | $12.5B | $11.5B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $1.7B | $1.2B | $72.0M | $2.5B | $1.3B | $2.2B | $1.1B | $2.7B |
| Diluted EPS | $0.83 | $0.60 | $0.05 | $1.20 | $0.64 | $1.08 | $0.54 | $1.31 |
| Operating cash flow | $2.3B | $5.6B | $4.4B | $2.0B | $3.9B | $6.3B | $2.0B | $1.1B |
| Free cash flow | $2.1B | $5.3B | $4.1B | $1.7B | $3.6B | $6.0B | $1.6B | $757.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 13.8% | 10.2% | 0.6% | 21.9% | 10.7% | 18.0% | 8.7% | 23.3% |
Company news
Jul 20, 2026
- 43m agoSector Update: Healthcare Stocks Fall Late Afternoonfinance.yahoo.com
- 1h agoBristol Myers Squibb expands NVIDIA AI supercomputer for drug discoveryqz.com
- 1h agoMerck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.finance.yahoo.com
- 4h agoTop Midday Stories: Brookfield, CPP Investments to Acquire LXP; Google Working on New Server Chipfinance.yahoo.com
- 7h agoBristol Myers Squibb expands Nvidia AI infrastructure for drug discoveryinvestorshub.advfn.com
- 7h agoAlexandria Real Estate Equities, Inc. Delivers 427,000 RSF Innovative Research & Development Hub for a Multinational Pharmaceutical Company at the Campus Point by Alexandria Megacampus™ in San Diegofinance.yahoo.com
- 9h agoBristol Myers buys Nvidia's latest AI computing system for drug researchfinance.yahoo.com
- 9h agoBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIAfinance.yahoo.com
- 11h agoBristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharmadive.com
- 14h agoWhat Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.finance.yahoo.com
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Haller Julia A | Option exercise | 20,460 | $53.76 | $1.1M | filing |
| 2026-06-03 | Short Bartie Wendy· EVP, Corporate Affairs | Tax withholding | 3,876 | $54.72 | $212,094.72 | filing |
| 2026-06-03 | Short Bartie Wendy· EVP, Corporate Affairs | Option exercise | 8,040 | $0.00 | $0.00 | filing |
| 2026-05-01 | Lenkowsky Adam· EVP, Chief Commercial Officer | Tax withholding | 599 | $58.22 | $34,873.78 | filing |
| 2026-05-01 | Lenkowsky Adam· EVP, Chief Commercial Officer | J | 203 | $0.00 | $0.00 | filing |
| 2026-05-01 | Lenkowsky Adam· EVP, Chief Commercial Officer | Option exercise | 1,373 | $0.00 | $0.00 | filing |
| 2026-04-01 | Elkins David V· EVP, Chief Financial Officer | Sale | 25,519 | $61.60 | $1.6M | filing |
| 2026-04-01 | Elkins David V· EVP, Chief Financial Officer | Sale | 4,481 | $62.05 | $278,046.05 | filing |
| 2026-04-01 | Shanahan Karin· EVP, Chief Supply Chain & Ops | Tax withholding | 1,692 | $61.73 | $104,447.16 | filing |
| 2026-04-01 | Shanahan Karin· EVP, Chief Supply Chain & Ops | Option exercise | 3,307 | $0.00 | $0.00 | filing |
| 2026-03-10 | BOERNER CHRISTOPHER S.· Chief Executive Officer | Tax withholding | 10,518 | $60.13 | $632,447.34 | filing |
| 2026-03-10 | Elkins David V· EVP, Chief Financial Officer | Tax withholding | 10,240 | $60.13 | $615,731.20 | filing |
| 2026-03-10 | Shanahan Karin· EVP, Chief Supply Chain & Ops | Tax withholding | 5,145 | $60.13 | $309,368.85 | filing |
| 2026-03-10 | BOERNER CHRISTOPHER S.· Chief Executive Officer | Tax withholding | 4,632 | $60.13 | $278,522.16 | filing |
| 2026-03-10 | Meyers Gregory Scott· EVP, Chief Digital & Tech Off. | Tax withholding | 4,267 | $60.13 | $256,574.71 | filing |
| 2026-03-10 | Plenge Robert M· EVP, Chief Research Officer | Tax withholding | 3,172 | $60.13 | $190,732.36 | filing |
| 2026-03-10 | Lenkowsky Adam· EVP, Chief Commercial Officer | Tax withholding | 3,125 | $60.13 | $187,906.25 | filing |
| 2026-03-10 | BOERNER CHRISTOPHER S.· Chief Executive Officer | Tax withholding | 3,073 | $60.13 | $184,779.49 | filing |
| 2026-03-10 | BOERNER CHRISTOPHER S.· Chief Executive Officer | Tax withholding | 3,006 | $60.13 | $180,750.78 | filing |
| 2026-03-10 | Elkins David V· EVP, Chief Financial Officer | Tax withholding | 2,991 | $60.13 | $179,848.83 | filing |
| 2026-03-10 | Elkins David V· EVP, Chief Financial Officer | Tax withholding | 2,883 | $60.13 | $173,354.79 | filing |
| 2026-03-10 | Lenkowsky Adam· EVP, Chief Commercial Officer | Tax withholding | 2,146 | $60.13 | $129,038.98 | filing |
| 2026-03-10 | Shanahan Karin· EVP, Chief Supply Chain & Ops | Tax withholding | 1,503 | $60.13 | $90,375.39 | filing |
| 2026-03-10 | Gallman Cari· EVP, General Counsel | Tax withholding | 1,354 | $60.13 | $81,416.02 | filing |
| 2026-03-10 | Poole Ahn Amanda· EVP, Chief People Officer | Tax withholding | 1,256 | $60.13 | $75,523.28 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.